Involvement of the STAT3-Th17 axis in viral myocarditis induced by Coxsackievirus B3. (12th October 2011)

• Record Type: Journal Article
• Authors: Yuluan, Yan; Yuluan, Yan; Yu, Pang; Weifeng, Wu; Fan, Yang; Qing, Kong; Yanlan, Huang
• Is Part Of: Heart. Volume 97(2011)Supplement 3
• Page Start: A24
• Page End: A25
• Publication Date: 2011-10-12
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2011-300867.70
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: This study was designed to explore whether the STAT3-Th17 axis is involved in the pathology of viral myocarditis (VMC) induced by Coxsackievirus B3 (CVB3). Methods: We induced VMC with male BALB/c mice by CVB3 intraperitoneal injection (n=48), mice intraperitoneal with phosphate-buffered solution (PBS) were taken as controls (n=30). STAT3 mRNA expression in the myocardium of mice was assessed by semi-quantitative RT-PCR. Phosphorylated-STAT3 (p-STAT3) protein expression in the myocardium and spleens was evaluated by Western-blot. Splenic CD4+T cells of VMC mice were isolated by immunomagnetic beads and cultured in vitro for 48 h with S3I-201(a selective STAT3 inhibitor), p-STAT3 protein expression, the percentages of Th17 cells, IL-17 mRNA expression, IL-17 protein level in supernatants in the cultured CD4+T cells were detected by Western-blot, flow cytometric analysis, semi-quantitative RT-PCR, enzyme-linked immunosorbent assay, respectively. Results: The expression of STAT3 mRNA in myocardium and p-STAT3 protein expression in myocardium and spleen tissues in VMC group increased significantly from 1 to 6 weeks after CVB3 injection, the highest levels were observed on the fourth week. The expression of p-STAT3 protein and Th17 cells proliferation in cultured CD4+ T cells were greatly inhibited by administration of S3I-201 (200 μM, 500 μM), correspondingly, IL-17 mRNA expression and IL-17 protein level in the supernatants decreased dramatically. Conclusions: The STAT3-Th17 axis is involved in the pathology of VMC induced by CVB3. Blocking the STAT3-Th17 axis by a selective STAT3 inhibitor S3I-201 may be a potential therapeutic target for VMC.